Dabur India Ltd
Dabur India Ltd
Consumer Goods F&OKey Fundamentals
MidcapPersonal CareConsumer GoodsInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Dabur India Ltd insights
62 extracted metrics + investor summaries across FY13–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company has been maintaining a healthy dividend payout of 70.1%
Weaknesses
1- The company has delivered a poor sales growth of 6.65% over past five years.
Growth Rate
AI Analysis — Bull vs Bear
Dabur India Ltd is a ₹72,803 crore FMCG company trading at a PE of 37.2x with a 5-year compounded sales CAGR of 7% and profit CAGR of just 2%. FY26 consolidated revenue grew 5% to ₹13,193 crore and net profit grew 7.4% to ₹1,869 crore, while the stock has declined 21% over the past one year, underperforming the broader market.
- Q4 FY26 net profit surged 16% YoY to ₹362 crore, indicating an earnings recovery trajectory after several muted quarters
- Consistent dividend payout ratio of 70.1% with a current dividend yield of 2.01%, providing income support in a declining stock price environment
- Rural demand outpacing urban by 350 basis points in Q4 FY26, benefiting Dabur's rural-heavy distribution which reaches over 100,000 villages
- India FMCG business grew 9.5% in Q1 FY27 with underlying volume growth of 5%, signalling improving domestic momentum
- Badshah Masala integration progressing well with 13.3% revenue growth and ~11% volume growth, reaching an exit run rate of ₹400 crore and expanding into new geographies
- E-commerce channel grew 54% in Q4 FY26, diversifying revenue mix away from traditional trade dependence
- 10-year average ROE of 21% demonstrates long-term capital efficiency, even though the most recent year dipped to 17%
- Ad spends rose 14% to ₹149 crore in Q4 FY26, reflecting management willingness to invest behind brands for future volume recovery
- Stock has delivered negative returns over 1-year (-21%), 3-year (-10% CAGR), and 5-year (-7% CAGR) periods, significantly destroying shareholder value
- 5-year compounded profit growth of only 2% indicates prolonged earnings stagnation relative to the premium PE of 37.2x
- Q4 FY26 volume growth of 6% lagged behind peers Marico (9%) and Godrej Consumer (8%), pointing to market share pressure
- Full-year FY26 revenue growth of just 5% to ₹13,193 crore remains well below what a 37x PE multiple typically warrants
- ROE has declined from a 10-year average of 21% to 17% in the latest year, reflecting diminishing return on capital efficiency
- 10-year sales CAGR of only 5% suggests structural low-single-digit topline growth, limiting scope for re-rating
- Price-to-book of 6.34x is elevated for a business growing revenue at mid-single digits, implying limited margin of safety
- International business faces currency headwinds and geopolitical risks across MENA, Turkey, and Africa markets, constraining consolidated growth
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- US FDA warning on Silvassa plant Aug 6
FDA issued warning letter dated July 24 citing data integrity issues at Dabur's Silvassa manufacturing plant, requiring response within 15 working days.
- FSSAI labelling action on foods Aug 4
FSSAI issued order on product labelling affecting specific food items in Dabur's portfolio. High Court stayed the ban on Aug 7 but matter remains pending.
- Q1 net profit surges 15% Jul 29
Q1 FY27 net profit rose 15% to ₹591 crore, consolidated revenue up 10.6% to ₹3,764 crore, India FMCG business grew 9.5%.
- ESG rating upgraded to Strong Jul 30
Crisil upgraded Dabur's ESG rating to Strong, citing robust performance on environmental and governance parameters.
- ₹5.50 final dividend approved Aug 6
Shareholders approved ₹5.50 per share final dividend for FY26 at 51st AGM held August 6, 2026.
- Double-digit volume growth target Jul 30
Dabur targets double-digit sales volume growth for FY27 with PAT outpacing revenue, allocated ₹500 crore to Dabur Ventures for D2C acquisitions, and reported 18% hair oil value growth in Q1.
- New CEO Herjit Bhalla appointed Jul 29
Herjit S. Bhalla appointed CEO for India Business effective April 23, 2026, following board-approved internal restructuring on July 29.
- Acquisition talks with 2-3 firms Jul 29
Dabur executive confirmed active acquisition discussions with 2-3 firms; no deal values, targets, or timelines disclosed yet.
- GST audit penalty of ₹25 lakh Aug 4
Dabur paid ₹25.39 lakh penalty to close GST audit proceedings for FY21-FY24 related to ineligible ITC in Ghaziabad.
- AGM director reappointments approved Aug 7
Shareholders reappointed directors Saket Burman, Rajiv Mehrishi, and Mukesh Hari Butani; all seven resolutions passed with significant majority.
TL;DR: Dabur delivered a solid Q1 FY27 with 15% profit growth, healthy volume momentum, and an ESG upgrade reinforcing governance credentials. Key risks include the US FDA warning letter on the Silvassa plant requiring remediation and pending FSSAI regulatory proceedings on food labelling, though the High Court stay provides interim relief. The company's strategic posture is growth-oriented with ₹500 crore earmarked for D2C acquisitions and active M&A discussions. The trend is improving on fundamentals but regulatory overhangs need monitoring over the next quarter.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,130 | 3,204 | 3,255 | 2,815 | 3,349 | 3,029 | 3,355 | 2,830 | 3,405 | 3,191 | 3,559 | 3,038 | 3,764 |
| Expenses | 2,526 | 2,543 | 2,588 | 2,348 | 2,694 | 2,476 | 2,673 | 2,403 | 2,737 | 2,603 | 2,825 | 2,577 | 3,024 |
| Operating Profit | 605 | 661 | 667 | 466 | 655 | 553 | 682 | 427 | 667 | 588 | 734 | 461 | 741 |
| OPM % | 19% | 21% | 20% | 17% | 20% | 18% | 20% | 15% | 20% | 18% | 21% | 15% | 20% |
| Other Income | 110 | 117 | 127 | 129 | 129 | 152 | 129 | 141 | 144 | 140 | 126 | 175 | 173 |
| Interest | 24 | 28 | 36 | 35 | 33 | 47 | 44 | 39 | 35 | 40 | 31 | 40 | 37 |
| Depreciation | 97 | 98 | 97 | 107 | 109 | 111 | 109 | 117 | 114 | 115 | 117 | 122 | 121 |
| PBT | 593 | 651 | 661 | 453 | 642 | 546 | 658 | 412 | 663 | 573 | 711 | 474 | 756 |
| Tax % | 23% | 22% | 23% | 25% | 23% | 24% | 22% | 24% | 23% | 22% | 22% | 24% | 22% |
| Net Profit | 457 | 507 | 506 | 341 | 494 | 418 | 516 | 313 | 508 | 445 | 554 | 362 | 586 |
| EPS in Rs | 2.62 | 2.91 | 2.9 | 1.97 | 2.82 | 2.4 | 2.95 | 1.81 | 2.9 | 2.55 | 3.16 | 2.08 | 3.33 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7,795 | 7,780 | 7,614 | 7,722 | 8,515 | 8,685 | 9,562 | 10,889 | 11,530 | 12,404 | 12,563 | 13,193 | 13,552 |
| Expenses | 6,475 | 6,261 | 6,102 | 6,104 | 6,775 | 6,892 | 7,560 | 8,637 | 9,367 | 10,004 | 10,247 | 10,743 | 11,029 |
| Operating Profit | 1,320 | 1,518 | 1,512 | 1,617 | 1,740 | 1,792 | 2,002 | 2,252 | 2,162 | 2,400 | 2,316 | 2,450 | 2,524 |
| OPM % | 17% | 20% | 20% | 21% | 20% | 21% | 21% | 21% | 19% | 19% | 18% | 19% | 19% |
| Other Income | 154 | 217 | 296 | 291 | 222 | 205 | 325 | 308 | 445 | 482 | 551 | 585 | 613 |
| Interest | 40 | 48 | 54 | 53 | 60 | 50 | 31 | 39 | 78 | 124 | 164 | 145 | 147 |
| Depreciation | 115 | 133 | 143 | 162 | 177 | 220 | 240 | 253 | 311 | 399 | 446 | 469 | 476 |
| PBT | 1,319 | 1,554 | 1,611 | 1,693 | 1,725 | 1,728 | 2,056 | 2,269 | 2,219 | 2,359 | 2,258 | 2,420 | 2,513 |
| Tax % | 19% | 19% | 21% | 20% | 16% | 16% | 18% | 23% | 23% | 23% | 23% | 23% | — |
| Net Profit | 1,068 | 1,254 | 1,280 | 1,358 | 1,446 | 1,448 | 1,695 | 1,742 | 1,701 | 1,811 | 1,740 | 1,869 | 1,947 |
| EPS in Rs | 6.07 | 7.11 | 7.25 | 7.69 | 8.17 | 8.18 | 9.58 | 9.84 | 9.64 | 10.4 | 9.97 | 10.68 | 11.12 |
| Div. Payout % | 33% | 32% | 31% | 81% | 34% | 37% | 50% | 53% | 54% | 53% | 80% | 77% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 176 | 176 | 176 | 176 | 177 | 177 | 177 | 177 | 177 | 177 | 177 | 177 |
| Reserves | 3,178 | 3,995 | 4,671 | 5,530 | 5,455 | 6,429 | 7,487 | 8,205 | 8,796 | 9,689 | 10,623 | 11,242 |
| Borrowings | 734 | 805 | 975 | 938 | 699 | 522 | 509 | 1,030 | 1,174 | 1,365 | 950 | 1,287 |
| Other Liabilities | 2,019 | 1,956 | 1,910 | 2,058 | 2,106 | 2,209 | 2,661 | 2,872 | 3,505 | 3,885 | 4,479 | 4,773 |
| Total Liabilities | 6,106 | 6,932 | 7,732 | 8,702 | 8,437 | 9,337 | 10,833 | 12,284 | 13,652 | 15,116 | 16,230 | 17,480 |
| Fixed Assets | 1,877 | 1,667 | 1,958 | 2,028 | 1,969 | 2,253 | 2,243 | 2,308 | 3,579 | 3,815 | 3,990 | 3,938 |
| CWIP | 50 | 45 | 42 | 42 | 64 | 147 | 147 | 168 | 175 | 232 | 169 | 139 |
| Investments | 1,813 | 2,691 | 3,240 | 3,805 | 3,359 | 2,800 | 4,160 | 6,220 | 6,265 | 6,933 | 7,468 | 8,947 |
| Other Assets | 2,365 | 2,529 | 2,492 | 2,827 | 3,045 | 4,137 | 4,283 | 3,589 | 3,633 | 4,136 | 4,603 | 4,456 |
| Total Assets | 6,106 | 6,932 | 7,732 | 8,702 | 8,437 | 9,337 | 10,833 | 12,284 | 13,652 | 15,116 | 16,230 | 17,480 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1,047 | 1,187 | 1,227 | 1,092 | 1,499 | 1,614 | 2,115 | 1,802 | 1,488 | 2,013 | 1,987 | 2,579 |
| Investing | -876 | -730 | -807 | -541 | 338 | -517 | -1,404 | -1,273 | -583 | -971 | -448 | -1,279 |
| Financing | -417 | -374 | -339 | -577 | -1,888 | -1,043 | -613 | -490 | -1,035 | -1,161 | -1,405 | -1,236 |
| Net Cash Flow | -245 | 82 | 81 | -27 | -51 | 54 | 97 | 38 | -130 | -119 | 133 | 64 |
| Free Cash Flow | 796 | 998 | 741 | 891 | 1,274 | 1,213 | 1,808 | 1,433 | 1,003 | 1,453 | 1,448 | 2,180 |
| CFO/OP | 97 | 97 | 102 | 88 | 106 | 107 | 122 | 97 | 92 | 104 | 103 | 122 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 33 | 38 | 31 | 33 | 36 | 34 | 21 | 22 | 27 | 26 | 26 | 20 |
| Inventory Days | 136 | 150 | 153 | 169 | 154 | 164 | 178 | 169 | 158 | 149 | 175 | 166 |
| Days Payable | 153 | 182 | 181 | 190 | 172 | 176 | 197 | 178 | 171 | 186 | 215 | 212 |
| Cash Conversion Cycle | 16 | 6 | 3 | 13 | 17 | 22 | 3 | 12 | 14 | -10 | -14 | -26 |
| Working Capital Days | -17 | 0 | -7 | -1 | -5 | 9 | -9 | -14 | -13 | -17 | -13 | -42 |
| ROCE % | 36% | 35% | 31% | 28% | 28% | 28% | 27% | 27% | 23% | 22% | 20% | 20% |
Documents
Frequently Asked Questions about Dabur India Ltd
What does Dabur India Ltd do?
Where is Dabur India Ltd (DABUR) listed?
Which sector does Dabur India Ltd belong to?
What is the market capitalisation of Dabur India Ltd?
What is the PE ratio of Dabur India Ltd?
What is the 52-week high and low of Dabur India Ltd?
Does Dabur India Ltd pay dividends?
What is the Return on Equity (ROE) of Dabur India Ltd?
How can I research Dabur India Ltd on Tapetide?
Company Information
Dabur is India’s leading FMCG, Ayurvedic and natural health care company with wide network distribution across world. [1]